Page 3 - Prime Editor News Today

Prime Medicine (NYSE:PRME – Get Free Report) is one of 288 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Prime Medicine to related companies based on the strength of its valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk. Profitability […]

Prime Medicine (NYSE:PRME – Get Free Report) is one of 273 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Prime Medicine to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings. Profitability This table […]

Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well

Prime Medicine (NYSE:PRME – Get Free Report) and Biogen (NASDAQ:BIIB – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership. Profitability This table compares Prime Medicine and Biogen’s net […]

Prime Medicine (NYSE:PRME – Get Free Report) and Replimune Group (NASDAQ:REPL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares Prime […]

Prime Medicine (NYSE:PRME – Get Free Report) and Quince Therapeutics (NASDAQ:QNCX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation. Insider and Institutional Ownership 47.4% of Prime […]

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Analyst Recommendations This is a summary of […]

Prime Medicine, Inc. (NYSE:PRME – Get Free Report)’s stock price fell 8.6% during mid-day trading on Wednesday . The stock traded as low as $13.50 and last traded at $13.56. 95,332 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 276,636 shares. The stock had previously closed at […]

Prime Medicine, Inc. (NYSE:PRME – Get Rating) major shareholder 2019 Gp L.L.C. Gv sold 6,532 shares of the firm’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $15.02, for a total value of $98,110.64. The sale was disclosed in a legal filing with the Securities & […]

-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therap...